Gimv establishes prominent life sciences advisory board
Antwerp — European private equity firm Gimv has announced the formation of a life sciences advisory board. The new board consists of six experienced industry experts with expertise in drug and medical device development, company building, and mergers and acquisitions. Michel Darnaud (formerly responsible for cardiac surgery at LivaNova), Peter Hirth (former CEO of Plexxikon), Ismail Kola (former CSO at UCB), Kasim Kutay (CEO of Novo Holdings), Alexandre LeBeaut (CSO of Ipsen) and Edwin Moses (former CEO of Ablynx) will assist Gimv’s life sciences team with portfolio development, new deal origination and general industry trend analysis.
Gimv has invested in more than 80 life sciences companies since 1982 and has consistently generated outstanding returns. Success stories include Ablynx, Plexxikon, Devgen, Covagen Prosonix and Endosense. As part of the broader “Health & Care” platform, Gimv’s life sciences team invests in biotechnology and medical technology start-ups — both early and later stage. An investment volume of 10–25 million euros per company is targeted, with financing provided through Gimv’s own balance sheet as part of an evergreen structure. The Life Sciences team, led by partners Dr. Karl Nägler, Bram Vanparys and Patrick Van Beneden, currently manages a portfolio of eleven companies. The plan is to expand the portfolio to 15 to 20 companies in the coming years.
Dr. Karl Nägler, Partner Gimv Germany says: “The establishment of this advisory board illustrates Gimv’s ambitions in the fields of biotechnology and medical technology for the coming years. At Gimv, we want to support ambitious entrepreneurs as partners. Through our new advisory board, we are expanding our network and adding value to our portfolio.”
Bram Vanparys, Partner Gimv Belgium adds, “We are very pleased to establish a close collaboration with these renowned and successful experts, each of whom has already achieved great things in our industry. With this collaboration, we succeed in further enhancing the value Gimv offers to patients, portfolio companies and shareholders.”